Sugar Compositions for Treating Hemophilia A and/or Von Willebrand Disease
AssigneeCSL Behring GmbH
InventorsStefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
Claims18
A method of treating hemophilia A and/or von Willebrand disease, comprising administering an isolated sugar to a subject in need thereof, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
A method of treating hemophilia A and/or von Willebrand disease comprising administering to a subject in need thereof an isolated sugar, and von Willebrand factor,
- wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
A method of treating hemophilia A and/or von Willebrand disease comprising administering to a subject in need thereof a composition comprising von Willebrand factor and one or more sugars, wherein the sugar is galactose, fucose, N-acetylgalactosamine, or chemically modified derivatives thereof, and wherein the sugar is a monosaccharide or accessible residue of one or more oligosaccharides or glycopeptides.
-15. (canceled)
Dependencies are inferred from the claim text.